Urologix Announces Leadership Change
MINNEAPOLIS, Nov. 20, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (ULGX), the
leading provider of in-office procedures for the safe, durable and effective
treatment of BPH, today announced a leadership change. The company's Chief
Operating Officer Greg Fluet will become interim CEO following the decision of
Stryker Warren jr. to retire as CEO and a member of the Company's Board of
Directors effective November 30, 2012.
Mr. Fluet joined the Company as its Executive Vice President and Chief
Operating Officer in July 2008. Prior to joining Urologix, Mr. Fluet was an
Associate at Sapient Capital Management, LLC, a venture capital firm focused
on medical devices. In addition to his direct responsibilities as COO, Greg
has been a key participant in the Company's strategic planning process, recent
financing transaction and business development activities, including the
"The correct strategy and Leadership Team are now in place to take advantage
of our position as the clear market leader in the in-office space for the
treatment of BPH," stated Warren."Urologix' value proposition is meaningful
to all our constituents: patient, physician and payor.I am confident that
Greg has the skills to lead the Company during this transition period."
Mr. Warren came out of retirement to join the Company as CEO in June 2008.He
brought a 35 year track record as a health care services entrepreneur to the
Company.He had previously been the President and CEO of Urology Healthcare
Group whose wholly owned subsidiary, Urotech, remains Urologix' largest
customer.During his four year tenure as CEO, he revitalized the Company's
relationships with the urologic community, organized the original patient
education initiatives which have become the principal driver of the Company's
growth strategy, built a strong leadership team to include the recruitment of
Mr. Fluet and steered the Company through a difficult decline in the in-office
BPH therapy market.Mr. Warren will provide transition services to the Company
through March 29, 2013.
"Stryker provided the right leadership at a critical time in Urologix'
history.His urology relationships and commitment to patients and employees
helped transform the Company," said Mitchell Dann, Chairman."Greg has been a
key member of the executive team during Stryker's tenure and the Board is
confident he can lead the Company during this transition period.The Board has
begun the process of looking for a permanent CEO."
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and
distributes minimally invasive medical products for the treatment of
obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix'
Cooled ThermoTherapy™ produces targeted microwave energy combined with a
unique cooling mechanism to protect healthy tissue and enhance patient
comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and
Targis® Control Units and the CTC Advance® and Targis® catheter families. The
Prostiva® RF Therapy System distributed by Urologix delivers radio frequency
energy directly into the prostate destroying prostate tissue, reducing
constriction of the urethra, and thereby relieving BPH voiding symptoms. Both
of these products provide safe, effective and lasting relief of the symptoms
and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic,
Inc., used under license. All other trademarks are the property of Urologix.
The Urologix, Inc. logo is available at
CONTACT: Brian J. Smrdel, Chief Financial Officer, (763) 475-7696
Urologix, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.